Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1Classical hematology 1

Conditions

Lymphoma, Non-Hodgkin 10Lymphoma, Follicular 10Lymphoma 8Lymphoma, Large B-Cell, Diffuse 7Leukemia, Lymphocytic, Chronic, B-Cell 7Recurrence 5Lymphoma, Mantle-Cell 5Neoplasms 3Lymphoma, B-Cell, Marginal Zone 2Lymphoma, B-Cell 2Triple Negative Breast Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Melanoma 1Leukemia, Prolymphocytic, B-Cell 1Leukemia, Hairy Cell 1Carcinoma, Renal Cell 1Carcinoma, Non-Small-Cell Lung 1Carcinoma 1Burkitt Lymphoma 1Anemia 1

Interventions

AP 1903 reagent 2thymoglobulin 1obinutuzumab 1fosphenytoin 1fludarabine phosphate 1fludarabine 1Whole-Body Irradiation 1Thiotepa 1Phenytoin 1Moxibustion 1Melphalan 1Ferric Oxide, Saccharated 1Darbepoetin alfa 1Cyclophosphamide 1CP protocol 1Busulfan 1Antilymphocyte Serum 1Alemtuzumab 16-(1H-indazol-6-yl)-N-(4-morpholinophenyl)imidazo(1,2-a)pyrazin-8-amine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Anemia × obinutuzumab × Clear all
NCT03010358 2023-08-08

Entospletinib and Obinutuzumab in Treating Patients With Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Non-Hodgkin Lymphoma

OHSU Knight Cancer Institute

Phase 1/2 Completed
24 enrolled 16 charts
Classical hematologyLymphoidOther hematologic neoplasm

Anemia, Leukemia, Hairy Cell, Lymphoma, Follicular, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell, Leukemia, Prolymphocytic, B-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡